<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01248923</url>
  </required_header>
  <id_info>
    <org_study_id>ARRAY-520-111</org_study_id>
    <nct_id>NCT01248923</nct_id>
  </id_info>
  <brief_title>A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Array Biopharma, now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Array BioPharma</source>
  <brief_summary>
    <textblock>
      This is a Phase 1 study during which patients with relapsed or refractory multiple myeloma&#xD;
      (MM) or plasma cell leukemia (PCL) will receive investigational study drug ARRY-520 and&#xD;
      bortezomib, with or without dexamethasone, with granulocyte-colony stimulating factor (G-CSF)&#xD;
      support.&#xD;
&#xD;
      This study has 2 parts. In the first part, patients will receive increasing doses of study&#xD;
      drug (2 dosing schedules will be evaluated) in combination with (1) bortezomib with G-CSF&#xD;
      support or (2) bortezomib and dexamethasone with G-CSF support, in order to achieve the&#xD;
      highest dose of study drug possible that will not cause unacceptable side effects.&#xD;
      Approximately 45 patients from the US will be enrolled in Part 1 (Active, not recruiting).&#xD;
&#xD;
      In the second part of this study, patients will receive the best dose(s) and schedule(s) of&#xD;
      study drug, in combination with bortezomib ± dexamethasone + G-CSF, determined from the first&#xD;
      part of the study and will be followed to see what side effects the combination causes and&#xD;
      what effectiveness the combination has, if any, in treating the cancer. Approximately 42&#xD;
      patients from the US will be enrolled in Part 2 (Active, not recruiting).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Characterize the safety profile of the study drug in combination with bortezomib ± dexamethasone + G-CSF in terms of adverse events, clinical laboratory tests and electrocardiograms.</measure>
    <time_frame>Part 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Establish the maximum tolerated dose (MTD) of the study drug in combination with bortezomib ± dexamethasone + G-CSF.</measure>
    <time_frame>Part 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess the efficacy of study drug in combination with bortezomib ± dexamethasone + G-CSF in terms of best overall response</measure>
    <time_frame>Part 2</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the efficacy of study drug in combination with bortezomib ± dexamethasone + G-CSF in terms of duration of response, time to progression, treatment-free interval and time to next treatment.</measure>
    <time_frame>Part 1 and Part 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize the safety profile of the study drug in combination with bortezomib ± dexamethasone + G-CSF in terms of adverse events, clinical laboratory tests and electrocardiograms.</measure>
    <time_frame>Part 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the pharmacokinetic (PK) drug interactions between ARRY-520 and bortezomib in terms of plasma concentration-time profiles.</measure>
    <time_frame>Part 2</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Multiple Myeloma, Plasma Cell Leukemia</condition>
  <arm_group>
    <arm_group_label>ARRY-520 (Schedule 1) + bortezomib + G-CSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ARRY-520 (Schedule 1) + bortezomib + dexamethasone + G-CSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ARRY-520 (Schedule 2) + bortezomib + dexamethasone + G-CSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARRY-520, KSP(Eg5) inhibitor; intravenous</intervention_name>
    <description>Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule.</description>
    <arm_group_label>ARRY-520 (Schedule 1) + bortezomib + dexamethasone + G-CSF</arm_group_label>
    <arm_group_label>ARRY-520 (Schedule 2) + bortezomib + dexamethasone + G-CSF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib, proteasome inhibitor; intravenous or subcutaneous</intervention_name>
    <description>Part 1: standard of care; Part 2: standard of care determined in Part 1.</description>
    <arm_group_label>ARRY-520 (Schedule 1) + bortezomib + dexamethasone + G-CSF</arm_group_label>
    <arm_group_label>ARRY-520 (Schedule 2) + bortezomib + dexamethasone + G-CSF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone, steroid; oral</intervention_name>
    <description>Part 1: standard of care; Part 2: standard of care determined in Part 1.</description>
    <arm_group_label>ARRY-520 (Schedule 1) + bortezomib + dexamethasone + G-CSF</arm_group_label>
    <arm_group_label>ARRY-520 (Schedule 2) + bortezomib + dexamethasone + G-CSF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous</intervention_name>
    <description>Part 1: standard of care; Part 2: standard of care.</description>
    <arm_group_label>ARRY-520 (Schedule 1) + bortezomib + dexamethasone + G-CSF</arm_group_label>
    <arm_group_label>ARRY-520 (Schedule 2) + bortezomib + dexamethasone + G-CSF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARRY-520, KSP(Eg5) inhibitor; intravenous</intervention_name>
    <description>Part 1: multiple dose, escalating</description>
    <arm_group_label>ARRY-520 (Schedule 1) + bortezomib + G-CSF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib, proteasome inhibitor; intravenous or subcutaneous</intervention_name>
    <description>Part 1: standard of care</description>
    <arm_group_label>ARRY-520 (Schedule 1) + bortezomib + G-CSF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous</intervention_name>
    <description>Part 1: standard of care</description>
    <arm_group_label>ARRY-520 (Schedule 1) + bortezomib + G-CSF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria (Part 1 and Part 2):&#xD;
&#xD;
          -  Confirmed relapsed or refractory MM (measurable disease) or PCL.&#xD;
&#xD;
          -  Prior treatment regimens for Part 1: Patients should have received at least 2 prior&#xD;
             treatment regimens. Prior treatment must have included at least one full cycle of a&#xD;
             proteasome inhibitor (e.g., bortezomib or carfilzomib) and at least one full cycle of&#xD;
             an IMiD (e.g., thalidomide, lenalidomide or pomalidomide).&#xD;
&#xD;
          -  Prior treatment regimens for Part 2: Patients should have received 1 to 3 prior&#xD;
             treatment regimens. Prior treatment could have included bortezomib only if the disease&#xD;
             was not refractory to treatment with bortezomib (refractory defined as documented&#xD;
             progression on therapy or within 60 days of completing treatment with bortezomib).&#xD;
&#xD;
          -  The disease should have progressed per IMWG criteria during or after the last prior&#xD;
             treatment regimen.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1.&#xD;
&#xD;
          -  Adequate hematology laboratory values without transfusion support and without&#xD;
             hematological growth factor support within 2 weeks of screening.&#xD;
&#xD;
          -  Adequate liver and renal function.&#xD;
&#xD;
          -  Additional criteria exist.&#xD;
&#xD;
        Key Exclusion Criteria (Part 1 and Part 2):&#xD;
&#xD;
          -  Primary amyloidosis.&#xD;
&#xD;
          -  Peripheral neuropathy ≥ Grade 2 or neuropathy with pain, regardless of grade.&#xD;
&#xD;
          -  Concomitant malignancies or previous malignancies with less than a 3-year disease free&#xD;
             interval at the time of enrollment (patients with adequately resected basal or&#xD;
             squamous cell carcinoma of the skin, carcinoma in situ of the cervix or Stage A low&#xD;
             grade prostate cancer may enroll irrespective of the time of diagnosis).&#xD;
&#xD;
          -  Autologous or allogeneic stem cell or bone marrow transplant within 3 months prior to&#xD;
             first dose of study drug.&#xD;
&#xD;
          -  Treatment with an investigational medicinal product or device within 28 days prior to&#xD;
             first dose of study drug.&#xD;
&#xD;
          -  Cytotoxic therapy or monoclonal antibodies within 21 days prior to first dose of study&#xD;
             drug.&#xD;
&#xD;
          -  Radiotherapy within 21 days prior to first dose of study drug (if the radiation portal&#xD;
             covered ≤ 5% of the bone marrow reserve, the patient may be enrolled irrespective of&#xD;
             the end date of radiotherapy).&#xD;
&#xD;
          -  Major surgery within 14 days and minor surgery within 7 days prior to first dose of&#xD;
             study drug.&#xD;
&#xD;
          -  Corticosteroid doses &gt; 10 mg/day of prednisone or equivalent within 14 days prior to&#xD;
             first dose of study drug.&#xD;
&#xD;
          -  Known positive serology for the human immunodeficiency virus (HIV), hepatitis B and/or&#xD;
             active hepatitis C.&#xD;
&#xD;
          -  Additional criteria exist.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clearview Cancer Institute</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Clinical Research Center, Inc.</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85715</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University, Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associates in Oncology/Hematology</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charleston Hematology Oncology Associates</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Jones Clinic</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Charles A. Sammons Cancer Center at Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>November 24, 2010</study_first_submitted>
  <study_first_submitted_qc>November 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2010</study_first_posted>
  <last_update_submitted>September 28, 2020</last_update_submitted>
  <last_update_submitted_qc>September 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>relapsed multiple myeloma</keyword>
  <keyword>plasma cell dyscrasia</keyword>
  <keyword>plasmacytoma</keyword>
  <keyword>kinesin spindle protein</keyword>
  <keyword>anti-mitotic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Leukemia, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Filanesib</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
    <mesh_term>Proteasome Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

